Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at...

Area of Science:

• Microbiology and Infectious Diseases
• Gastroenterology
• Clinical Research

Background:

• Vancomycin-resistant Enterococcus (VRE) is a significant healthcare-associated pathogen.
• VRE poses a particular risk to transplant recipients and immunocompromised individuals.
• Recurrent Clostridium difficile infection (CDI) is a common complication in vulnerable patient populations.

Purpose of the Study:

• To conduct a post hoc analysis of the PUNCH CD study.
• To assess vancomycin-resistant Enterococcus (VRE) stool clearance.
• To evaluate the efficacy of RBX2660, a microbiota-based therapeutic, in patients with recurrent Clostridium difficile infection (CDI).

Main Methods:

• 34 patients with recurrent CDI received 1-2 doses of RBX2660.
• Voluntary stool samples were collected at baseline and multiple follow-up points (7, 30, 60 days, 6 months).
• VRE detection utilized bile esculin azide agar with vancomycin and Gram staining, with confirmation by Etest.

Main Results:

• Of 30 patients with available VRE status, 19 (63.3%) were initially VRE-negative.
• Eleven patients (36.7%) were initially VRE-positive; 8 (72.7%) converted to VRE-negative status by the last follow-up.
• One VRE-positive patient died, one remained persistently positive, and one had a late positive retest.

Conclusions:

• RBX2660 demonstrated potential for achieving vancomycin-resistant Enterococcus (VRE) clearance in a recurrent Clostridium difficile infection (CDI) patient cohort.
• Despite the small sample size, the results suggest a possible therapeutic benefit for VRE-positive patients treated with this microbiota-based drug.
• Further investigation is warranted to confirm these findings in larger, prospective studies.